Cancer Research

Overcoming Life After Cancer: Challenges and Support for Young Survivors
Research & Development Overcoming Life After Cancer: Challenges and Support for Young Survivors

Advancements in cancer diagnosis and treatment have significantly improved survival rates, leading to a growing number of young cancer survivors. This demographic shift brings unique challenges as these individuals navigate life post-treatment, facing physical, emotional, and social upheavals. The

Rising Breast Cancer Rates Among Indian Women Aged 55-64 Demand Action
Research & Development Rising Breast Cancer Rates Among Indian Women Aged 55-64 Demand Action

Breast Cancer Awareness Month has highlighted a pressing health crisis among Indian women, particularly those aged 55 to 64. A recent report by Healthians reveals that 16% of women in this demographic are affected by breast cancer. This alarming statistic underscores the urgent need for awareness,

FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus
Research & Development FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus

The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus

Oncology Patent Leaders 2024: Analyzing Innovation in Pharma Industry
Research & Development Oncology Patent Leaders 2024: Analyzing Innovation in Pharma Industry

The pharmaceutical industry has long been a battleground for innovation, with companies around the globe constantly striving to outpace each other in developing cutting-edge therapies. Oncology, the branch of medicine that deals with cancer, has emerged as a focal point of this dynamic competition.

Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma
Research & Development Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma

The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of

How Will MilliporeSigma's $76M ADC Investment Change Cancer Treatment?
Research & Development How Will MilliporeSigma's $76M ADC Investment Change Cancer Treatment?

MilliporeSigma, a prominent player in the life sciences sector, has launched a transformative $76 million investment dedicated to expanding its ADC (antibody-drug conjugates) manufacturing capabilities at its St. Louis, Missouri facility. This monumental investment encapsulates the extensive

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later